The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the
reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes
mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic
blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially
beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2
inhibitor approved for use in the United States.
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2
inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Rights & PermissionsPrintExport